Improved Gene Therapy Vectors for the Treatment of Glycogen Storage Disease Type Ia (GSD-1a)
GSD-Ia is an inherited disorder of metabolism associated with life-threatening hypoglycemia, hepatic malignancy, and renal failure caused by the deficiency of glucose-6-phosphatase-alpha (G6Pase-alpha or G6PC). Current therapy, which primarily consists of dietary modification, fails to prevent long-term complications in many patients, including growth failure, gout, pulmonary hypertension, renal dysfunction, osteoporosis, and hepatocellular adenomas (HCA). Gene therapy-based techniques, which directly address the underlying genetic deficiency driving the disorder, offer the prospect of long-term remission in patients with GSD-Ia.
Researchers at the NIH National Institute for Child Health and Human Development developed adeno-associated viral (AAV) vectors for the treatment of glycogen storage disease type Ia (GSD-Ia).This technology describes new AAV vectors for the delivery of corrective genes that express modified human G6Pase-alpha proteins, directed by the tissue-specific human G6PC promoter/enhancer.
This technology can be independently licensed for development as a therapy. The NICHD inventor is also interested in the mechanisms by which GSD-1a may lead to hepatic malignancy and a collaboration project may be considered.
Competitive Advantages:
- Protein coding sequences are modified from the wildtype human sequence for enhanced enzymatic activity.
Commercial Applications:
- Gene therapy vector for the delivery of a corrective gene to treat of GSD-Ia.
- Useful in development of a combined pharmaceutical plus gene therapy approach to treat adult GSD-1a patients at risk of hepatocellular carcinoma.
Related Inventions
-
E-039-2015
TAB-3939
Gene Therapy Vector for the Treatment of Glycogen Storage Disease Type Ia (GSD-Ia)
Patents
- US Patent 10,113,183
Filed on 2017-04-21
Status: Issued - US
Provisional (PRV) 61/908,861
Filed on 2013-11-26
Status: Abandoned - Patent Cooperation Treaty
(PCT) PCT/US2014/067415
Filed on 2014-11-25
Status: Expired - Australia
National Stage 2014354839
Filed on 2014-11-25
Status: Issued - Brazil
National Stage BR112016011997-5
Filed on 2014-11-25
Status: Issued - Canada
National Stage 2930872
Filed on 2014-11-25
Status: Issued - China
National Stage 201480074046.6
Filed on 2014-11-25
Status: Issued - Colombia
National Stage 16162610
Filed on 2016-06-21
Status: Abandoned - European Patent
National Stage 14812375.5
Filed on 2014-11-25
Status: Issued - Israel
National Stage 245659
Filed on 2016-05-16
Status: Issued - Japan
National Stage 2016-554828
Filed on 2014-11-25
Status: Issued - Mexico
National Stage MX/a/2016/006774
Filed on 2014-11-25
Status: Issued - US Patent 9,644,216
Filed on 2016-05-24
Status: Issued - European Patent
Divisional (DIV) 18186594.0
Filed on 2018-07-31
Status: Issued - Belgium
European patent (EP) 14812375.5
Filed on 2014-11-25
Status: Issued - Switzerland
European patent (EP) 14812375.5
Filed on 2014-11-25
Status: Issued - Germany
European patent (EP) 14812375.5
Filed on 2014-11-25
Status: Issued - Spain
European patent (EP) 14812375.5
Filed on 2014-11-25
Status: Issued - France
European patent (EP) 14812375.5
Filed on 2014-11-25
Status: Issued - United Kingdom
European patent (EP) 14812375.5
Filed on 2014-11-25
Status: Issued - Italy
European patent (EP) 14812375.5
Filed on 2014-11-25
Status: Issued - The Netherlands
European patent